Applications of cardiac magnetic resonance in electrophysiology

Circulation: Arrhythmia and Electrophysiology

Volumn 2, Issue 1, 2009, Pages 63-71

  Nazarian, Saman ^a,c   Bluemke, David A ^b   Halperin, Henry R ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Ablation; Cardiomyopathy; Electrophysiology; Magnetic resonance imaging

Indexed keywords

GADOLINIUM;

CARDIOMYOPATHY; CATHETER ABLATION; CHAGAS DISEASE; DIAGNOSTIC VALUE; ECHOCARDIOGRAPHY; HEART ARRHYTHMIA; HEART CYCLE; HEART ELECTROPHYSIOLOGY; HEART MUSCLE; HEART MUSCLE BIOPSY; HEART RIGHT VENTRICLE DYSPLASIA; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; IMAGE ENHANCEMENT; MYOCARDITIS; NUCLEAR MAGNETIC RESONANCE; PATIENT SAFETY; PRIORITY JOURNAL; PULMONARY VEIN; REENTRY ARRHYTHMIA; REVIEW; RISK ASSESSMENT; SARCOIDOSIS; SARCOMERE; SCAR FORMATION;

ARRHYTHMIAS, CARDIAC; CATHETER ABLATION; ELECTROPHYSIOLOGIC TECHNIQUES, CARDIAC; HEART CONDUCTION SYSTEM; HUMANS; MAGNETIC RESONANCE IMAGING; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT;

EID: 70349316443     PISSN: 19413149     EISSN: 19413084     Source Type: Journal    
DOI: 10.1161/CIRCEP.108.811562     Document Type: Review

References (100)

1. Spector PS. Diagnosis and management of sudden cardiac death. Heart. 2005; 91:408-413.
2. Macedo R, Schmidt A, Rochitte CE, Lima JA, Bluemke DA. MRI to assess arrhythmia and cardiomyopathies. J Magn Reson Imaging. 2006; 24:1197-1206.
3. Eichstaedt HW, Felix R, Danne O, Dougherty FC, Schmutzler H. Imaging of acute myocardial infarction by magnetic resonance tomography (MRT) using the paramagnetic relaxation substance gadolinium-DTPA. Cardiovasc Drugs Ther. 1989; 3:779 -788.
4. de Roos A, van Rossum AC, van der Wall E, Postema S, Doornbos J, Matheijssen N, van Dijkman PR, Visser FC, van Voorthuisen AE. Reperfused and nonreperfused myocardial infarction: diagnostic potential of Gd-DTPA-enhanced MR imaging. Radiology. 1989; 172: 717-720.
5. Van Rossum AC, Visser FC, Van Eenige MJ, Sprenger M, Valk J, Verheugt FW, Roos JP. Value of gadolinium-diethylene-triamine pentaacetic acid dynamics in magnetic resonance imaging of acute myocardial infarction with occluded and reperfused coronary arteries after thrombolysis. Am J Cardiol. 1990; 65:845- 851.
6. Holman ER, van Jonbergen HP, van Dijkman PR, van der Laarse A, de Roos A, van der Wall EE. Comparison of magnetic resonance imaging studies with enzymatic indexes of myocardial necrosis for quantification of myocardial infarct size. Am J Cardiol. 1993; 71:1036 -1040.
7. Lima JA, Judd RM, Bazille A, Schulman SP, Atalar E, Zerhouni EA. Regional heterogeneity of human myocardial infarcts demonstrated by contrast-enhanced MRI. Potential mechanisms. Circulation. 1995; 92: 1117-1125.
8. Kim RJ, Fieno DS, Parrish TB, Harris K, Chen EL, Simonetti O, Bundy J, Finn JP, Klocke FJ, Judd RM. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation. 1999; 100:1992-2002.
9. Simonetti OP, Kim RJ, Fieno DS, Hillenbrand HB, Wu E, Bundy JM, Finn JP, Judd RM. An improved MR imaging technique for the visualization of myocardial infarction. Radiology. 2001; 218:215-223.
10. Kim RJ, Wu E, Rafael A, Chen EL, Parker MA, Simonetti O, Klocke FJ, Bonow RO, Judd RM. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med. 2000; 343:1445-1453.
11. Kim RJ, Shah DJ, Judd RM. How we perform delayed enhancement imaging. J Cardiovasc Magn Reson. 2003; 5:505-514.
12. Ordovas KG, Reddy GP, Higgins CB. MRI in nonischemic acquired heart disease. J Magn Reson Imaging. 2008; 27:1195-1213.
13. Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, Shah PM, Spencer WH III, Spirito P, Ten Cate FJ, Wigle ED. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol. 2003; 42:1687-1713.
14. Devlin AM, Moore NR, Ostman-Smith I. A comparison of MRI and echocardiography in hypertrophic cardiomyopathy. Br J Radiol. 1999; 72:258 -264.
15. Moon JC, Fisher NG, McKenna WJ, Pennell DJ. Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography. Heart. 2004; 90: 645-649.
16. Rickers C, Wilke NM, Jerosch-Herold M, Casey SA, Panse P, Panse N, Weil J, Zenovich AG, Maron BJ. Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Circulation. 2005; 112:855- 861.
17. Choudhury L, Mahrholdt H, Wagner A, Choi KM, Elliott MD, Klocke FJ, Bonow RO, Judd RM, Kim RJ. Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2002; 40:2156 -2164.
18. Moon JC, McKenna WJ, McCrohon JA, Elliott PM, Smith GC, Pennell DJ. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol. 2003; 41:1561-1567.
19. Strohm O, Schulz-Menger J, Pilz B, Osterziel KJ, Dietz R, Friedrich MG. Measurement of left ventricular dimensions and function in patients with dilated cardiomyopathy. J Magn Reson Imaging. 2001; 13: 367-371.
20. McCrohon JA, Moon JC, Prasad SK, McKenna WJ, Lorenz CH, Coats AJ, Pennell DJ. Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation. 2003; 108:54 -59.
21. Soriano CJ, Ridocci F, Estornell J, Jimenez J, Martinez V, De Velasco JA. Noninvasive diagnosis of coronary artery disease in patients with heart failure and systolic dysfunction of uncertain etiology, using late gadolinium-enhanced cardiovascular magnetic resonance. J Am Coll Cardiol. 2005; 45:743-748.
22. Zimmermann O, Grebe O, Merkle N, Nusser T, Kochs M, Bienek- Ziolkowski M, Hombach V, Torzewski J. Myocardial biopsy findings and gadolinium enhanced cardiovascular magnetic resonance in dilated cardiomyopathy. Eur J Heart Fail. 2006; 8:162-166.
23. Lewin RF, Mor R, Spitzer S, Arditti A, Hellman C, Agmon J. Echocardiographic evaluation of patients with systemic sarcoidosis. Am Heart J. 1985; 110:116 -122.
24. Saeki M, Kitazawa H, Kodama M, Izumi T, Shibata A, Kido S, Masani F. Images in cardiovascular medicine. Cardiac sarcoidosis. 67Ga imaging and histology. Circulation. 1995; 91:2497-2498.
25. Ratner SJ, Fenoglio JJ Jr, Ursell PC. Utility of endomyocardial biopsy in the diagnosis of cardiac sarcoidosis. Chest. 1986; 90:528 -533.
26. Kurashima K, Shimizu H, Ogawa H, Ohka T, Nobata K, Ueno K, Rikimaru S, Fujimura M, Matsuda T. MR and CT in the evaluation of sarcoid myopathy. J Comput Assist Tomogr. 1991; 15:1004 -1007.
27. Vignaux O, Dhote R, Duboc D, Blanche P, Devaux JY, Weber S, Legmann P. Detection of myocardial involvement in patients with sarcoidosis applying T2-weighted, contrast-enhanced, and cine magnetic resonance imaging: initial results of a prospective study. J Comput Assist Tomogr. 2002; 26:762-767.
28. Vignaux O, Dhote R, Duboc D, Blanche P, Dusser D, Weber S, Legmann P. Clinical significance of myocardial magnetic resonance abnormalities in patients with sarcoidosis: a 1-year follow-up study. Chest. 2002; 122:1895-1901.
29. Vignaux O. Cardiac sarcoidosis: spectrum of MRI features. AJR Am J Roentgenol. 2005; 184:249 -254.
30. Smedema JP, Snoep G, van Kroonenburgh MP, van Geuns RJ, Cheriex EC, Gorgels AP, Crijns HJ. The additional value of gadoliniumenhanced MRI to standard assessment for cardiac involvement in patients with pulmonary sarcoidosis. Chest. 2005; 128:1629 -1637.
31. Marcus FI, Fontaine GH, Guiraudon G, Frank R, Laurenceau JL, Malergue C, Grosgogeat Y. Right ventricular dysplasia: a report of 24 adult cases. Circulation. 1982; 65:384 -398.
32. Blake LM, Scheinman MM, Higgins CB. MR features of arrhythmogenic right ventricular dysplasia. AJR Am J Roentgenol. 1994; 162: 809-812.
33. Midiri M, Finazzo M. MR imaging of arrhythmogenic right ventricular dysplasia. Int J Cardiovasc Imaging. 2001; 17:297-304.
34. Tandri H, Friedrich MG, Calkins H, Bluemke DA. MRI of arrhythmogenic right ventricular cardiomyopathy/dysplasia. J Cardiovasc Magn Reson. 2004; 6:557-563. (Pubitemid 39277127)
35. Jain A, Tandri H, Calkins H, Bluemke DA. Role of cardiovascular magnetic resonance imaging in arrhythmogenic right ventricular dysplasia. J Cardiovasc Magn Reson. 2008; 10:32.
36. Fontaine G, Fontaliran F, Zenati O, Guzman CE, Rigoulet J, Berthier JL, Frank R. Fat in the heart. A feature unique to the human species? Observational reflections on an unsolved problem. Acta Cardiol. 1999; 54:189-194.
37. Burke AP, Farb A, Tashko G, Virmani R. Arrhythmogenic right ventricular cardiomyopathy and fatty replacement of the right ventricular myocardium: are they different diseases? Circulation. 1998; 97: 1571-1580.
38. Tandri H, Saranathan M, Rodriguez ER, Martinez C, Bomma C, Nasir K, Rosen B, Lima JA, Calkins H, Bluemke DA. Noninvasive detection of myocardial fibrosis in arrhythmogenic right ventricular cardiomyopathy using delayed-enhancement magnetic resonance imaging. J Am Coll Cardiol. 2005; 45:98 -103. (Pubitemid 40052034)
39. Desai MY, Gupta S, Bomma C, Tandri H, Foo TK, Lima JA, Bluemke DA. The apparent inversion time for optimal delayed enhancement magnetic resonance imaging differs between the right and left ventricles. J Cardiovasc Magn Reson. 2005; 7:475-479.
40. Macedo R, Prakasa K, Tichnell C, Marcus F, Calkins H, Lima JA, Bluemke DA. Marked lipomatous infiltration of the right ventricle: MRI findings in relation to arrhythmogenic right ventricular dysplasia. AJR Am J Roentgenol. 2007; 188:W423-W427.
41. McKenna WJ, Thiene G, Nava A, Fontaliran F, Blomstrom-Lundqvist C, Fontaine G, Camerini F. Diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Task Force of the Working Group Myocardial and Pericardial Disease of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the International Society and Federation of Cardiology. Br Heart J. 1994; 71:215-218.
42. Shanes JG, Ghali J, Billingham ME, Ferrans VJ, Fenoglio JJ, Edwards WD, Tsai CC, Saffitz JE, Isner J, Furner S. Interobserver variability in the pathologic interpretation of endomyocardial biopsy results. Circulation. 1987; 75:401- 405.
43. Friedrich MG, Strohm O, Schulz-Menger J, Marciniak H, Luft FC, Dietz R. Contrast media-enhanced magnetic resonance imaging visualizes myocardial changes in the course of viral myocarditis. Circulation. 1998; 97:1802-1809.
44. Scott RL, Ratliff NB, Starling RC, Young JB. Recurrence of giant cell myocarditis in cardiac allograft. J Heart Lung Transplant. 2001; 20: 375-380.
45. Mahrholdt H, Goedecke C, Wagner A, Meinhardt G, Athanasiadis A, Vogelsberg H, Fritz P, Klingel K, Kandolf R, Sechtem U. Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. Circulation. 2004; 109: 1250-1258.
46. Shirani J, Freant LJ, Roberts WC. Gross and semiquantitative histologic findings in mononuclear cell myocarditis causing sudden death, and implications for endomyocardial biopsy. Am J Cardiol. 1993; 72: 952-957.
47. Kalil Filho R, de Albuquerque, CP. Magnetic resonance imaging in Chagas' heart disease. Sao Paulo Med J. 1995; 113:880-883.
48. Harris MA, Johnson TR, Weinberg PM, Fogel MA. Delayedenhancement cardiovascular magnetic resonance identifies fibrous tissue in children after surgery for congenital heart disease. J Thorac Cardiovasc Surg. 2007; 133:676-681.
49. Massumi A, Rasekh A, Saeed M, Flam S, Cheong B, Mojibian H, Razavi M. Organized incessant atrial arrhythmias in the setting of severe, isolated biatrial scarring. Pacing Clin Electrophysiol. 2008; 31: 666-675.
50. Peters D, Wylie J, Kissinger K, Hauser T, Botnar R, Essebag V, Josephson M, Manning W. Detection of pulmonary vein ablation with high resolution MRI. J Cardiovasc Magn Reson. 2006; 8:4 -5.
51. Peters DC, Wylie JV, Hauser TH, Kissinger KV, Botnar RM, Essebag V, Josephson ME, Manning WJ. Detection of pulmonary vein and left atrial scar after catheter ablation with three-dimensional navigator-gated delayed enhancement MR imaging: initial experience. Radiology. 2007; 243:690-695.
52. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med. 1999; 341:1882-1890.
53. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, Levine JH, Saksena S, Waldo AL, Wilber D, Brown MW, Heo M. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med. 1996; 335:1933-1940.
54. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown MW, Andrews ML. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002; 346:877- 883.
55. Bello D, Fieno DS, Kim RJ, Pereles FS, Passman R, Song G, Kadish AH, Goldberger JJ. Infarct morphology identifies patients with substrate for sustained ventricular tachycardia. J Am Coll Cardiol. 2005; 45: 1104-1108.
56. Yan AT, Shayne AJ, Brown KA, Gupta SN, Chan CW, Luu TM, Di Carli MF, Reynolds HG, Stevenson WG, Kwong RY. Characterization of the peri-infarct zone by contrast-enhanced cardiac magnetic resonance imaging is a powerful predictor of post-myocardial infarction mortality. Circulation. 2006; 114:32-39.
57. Schmidt A, Azevedo CF, Cheng A, Gupta SN, Bluemke DA, Foo TK, Gerstenblith G, Weiss RG, Marban E, Tomaselli GF, Lima JA, Wu KC. Infarct tissue heterogeneity by magnetic resonance imaging identifies enhanced cardiac arrhythmia susceptibility in patients with left ventricular dysfunction. Circulation. 2007; 115:2006 -2014.
58. The DETERMINE Trial (DEfibrillators To REduce Risk by MagnetIc ResoNance Imaging Evaluation). Available at: http://determinetrial.com/. Accessed on January 13, 2009.
59. Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med. 2000; 342:1778 -1785.
60. Varnava AM, Elliott PM, Mahon N, Davies MJ, McKenna WJ. Relation between myocyte disarray and outcome in hypertrophic cardiomyopathy. Am J Cardiol. 2001; 88:275-279.
61. Teraoka K, Hirano M, Ookubo H, Sasaki K, Katsuyama H, Amino M, Abe Y, Yamashina A. Delayed contrast enhancement of MRI in hypertrophic cardiomyopathy. Magn Reson Imaging. 2004; 22:155-161.
62. Dimitrow PP, Klimeczek P, Vliegenthart R, Pasowicz M, Oudkerk M, Podolec P, Tracz W, Dubiel JS. Late hyperenhancement in gadoliniumenhanced magnetic resonance imaging: comparison of hypertrophic cardiomyopathy patients with and without nonsustained ventricular tachycardia. Int J Cardiovasc Imaging. 2008; 24:77- 83; discussion 85-77.
63. Adabag AS, Maron BJ, Appelbaum E, Harrigan CJ, Buros JL, Gibson CM, Lesser JR, Hanna CA, Udelson JE, Manning WJ, Maron MS. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol. 2008; 51:1369 -1374.
64. Sugrue DD, Rodeheffer RJ, Codd MB, Ballard DJ, Fuster V, Gersh BJ. The clinical course of idiopathic dilated cardiomyopathy. A population-based study. Ann Intern Med. 1992; 117:117-123.
65. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE, Clapp- Channing N, Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005; 352:225-237.
66. Nazarian S, Bluemke DA, Lardo AC, Zviman MM, Watkins SP, Dickfeld TL, Meininger GR, Roguin A, Calkins H, Tomaselli GF, Weiss RG, Berger RD, Lima JA, Halperin HR. Magnetic resonance assessment of the substrate for inducible ventricular tachycardia in nonischemic cardiomyopathy. Circulation. 2005; 112:2821-2825.
67. Assomull RG, Prasad SK, Lyne J, Smith G, Burman ED, Khan M, Sheppard MN, Poole-Wilson PA, Pennell DJ. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol. 2006; 48:1977-1985.
68. Wu KC, Weiss RG, Thiemann DR, Kitagawa K, Schmidt A, Dalal D, Lai S, Bluemke DA, Gerstenblith G, Marban E, Tomaselli GF, Lima JA. Late gadolinium enhancement by cardiovascular magnetic resonance heralds an adverse prognosis in nonischemic cardiomyopathy. J Am Coll Cardiol. 2008; 51:2414-2421.
69. Marchlinski FE, Jessup M. Timing the implantation of implantable cardioverter-defibrillators in patients with nonischemic cardiomyopathy. J Am Coll Cardiol. 2006; 47:2483-2485.
70. Stevenson WG, Soejima K. Catheter ablation for ventricular tachycardia. Circulation. 2007; 115:2750 -2760.
71. Shammas RL, Movahed A. Sarcoidosis of the heart. Clin Cardiol. 1993; 16:462-472.
72. Corrado D, Basso C, Schiavon M, Thiene G. Screening for hypertrophic cardiomyopathy in young athletes. N Engl J Med. 1998; 339:364 -369.
73. Maron BJ, Shirani J, Poliac LC, Mathenge R, Roberts WC, Mueller FO. Sudden death in young competitive athletes. Clinical, demographic, and pathological profiles. JAMA. 1996; 276:199-204.
74. Badorff C, Zeiher AM, Hohnloser SH. Torsade de pointes tachycardia as a rare manifestation of acute enteroviral myocarditis. Heart. 2001; 86: 489-490.
75. Theleman KP, Kuiper JJ, Roberts WC. Acute myocarditis (predominately lymphocytic) causing sudden death without heart failure. Am J Cardiol. 2001; 88:1078 -1083.
76. Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation. 1997; 96:1180 -1184.
77. Hagar JM, Rahimtoola SH. Chagas' heart disease. Curr Probl Cardiol. 1995; 20:825-924.
78. Bellotti G, Bocchi EA, de Moraes AV, Higuchi ML, Barbero-Marcial M, Sosa E, Esteves-Filho A, Kalil R, Weiss R, Jatene A, Pileggi F. In vivo detection of Trypanosoma cruzi antigens in hearts of patients with chronic Chagas' heart disease. Am Heart J. 1996; 131:301-307.
79. Bestetti RB, Muccillo G. Clinical course of Chagas' heart disease: a comparison with dilated cardiomyopathy. Int J Cardiol. 1997; 60: 187-193.
80. de Paola AA, Gomes JA, Terzian AB, Miyamoto MH, Martinez Fo EE. Ventricular tachycardia during exercise testing as a predictor of sudden death in patients with chronic chagasic cardiomyopathy and ventricular arrhythmias. Br Heart J. 1995; 74:293-295.
81. Carrasco HA, Parada H, Guerrero L, Duque M, Duran D, Molina C. Prognostic implications of clinical, electrocardiographic and hemodynamic findings in chronic Chagas' disease. Int J Cardiol. 1994; 43: 27-38.
82. Rochitte CE, Oliveira PF, Andrade JM, Ianni BM, Parga JR, Avila LF, Kalil-Filho R, Mady C, Meneghetti JC, Lima JA, Ramires JA. Myocardial delayed enhancement by magnetic resonance imaging in patients with Chagas' disease: a marker of disease severity. J Am Coll Cardiol. 2005; 46:1553-1558.
83. De Ponti R, Verlato R, Bertaglia E, Del Greco M, Fusco A, Bottoni N, Drago F, Sciarra L, Ometto R, Mantovan R, Salerno-Uriarte JA. Treatment of macro-re-entrant atrial tachycardia based on electroanatomic mapping: identification and ablation of the mid-diastolic isthmus. Europace. 2007; 9:449-457.
84. Abrams DJ, Earley MJ, Sporton SC, Kistler PM, Gatzoulis MA, Mullen MJ, Till JA, Cullen S, Walker F, Lowe MD, Deanfield JE, Schilling RJ. Comparison of noncontact and electroanatomic mapping to identify scar and arrhythmia late after the Fontan procedure. Circulation. 2007; 115:1738-1746.
85. Seiler J, Schmid DK, Irtel TA, Tanner H, Rotter M, Schwick N, Delacretaz E. Dual-loop circuits in postoperative atrial macro re-entrant tachycardias. Heart. 2007; 93:325-330.
86. Chinushi M, Aizawa Y, Kitazawa H, Takahashi K, Washizuka T, Shibata A. Clockwise and counter-clockwise circulation of wavefronts around an anatomical obstacle as one mechanism of two morphologies of sustained ventricular tachycardia in patients after a corrective operation of tetralogy of Fallot. Pacing Clin Electrophysiol. 1997; 20: 2279-2281.
87. Perloff JK, Middlekauf HR, Child JS, Stevenson WG, Miner PD, Goldberg GD. Usefulness of post-ventriculotomy signal averaged electrocardiograms in congenital heart disease. Am J Cardiol. 2006; 98: 1646-1651.
88. Wylie JV Jr, Peters DC, Essebag V, Manning WJ, Josephson ME, Hauser TH. Left atrial function and scar after catheter ablation of atrial fibrillation. Heart Rhythm. 2008; 5:656-662.
89. Dong J, Dickfeld T, Dalal D, Cheema A, Vasamreddy CR, Henrikson CA, Marine JE, Halperin HR, Berger RD, Lima JA, Bluemke DA, Calkins H. Initial experience in the use of integrated electroanatomic mapping with three-dimensional MR/CT images to guide catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol. 2006; 17: 459-466.
90. Bunch TJ, Day JD. Novel ablative approach for atrial fibrillation to decrease risk of esophageal injury. Heart Rhythm. 2008; 5:624-627.
91. Daoud EG, Hummel JD, Houmsse M, Hart DT, Weiss R, Liu Z, Augostini R, Kalbfleisch S, Smith MC, Mehta R, Gangasani A, Raman SV. Comparison of computed tomography imaging with intraprocedural contrast esophagram: implications for catheter ablation of atrial fibrillation. Heart Rhythm. 2008; 5:975-980.
92. Nitz WR, Oppelt A, Renz W, Manke C, Lenhart M, Link J. On the heating of linear conductive structures as guide wires and catheters in interventional MRI. J Magn Reson Imaging. 2001; 13:105-114.
93. Peden CJ, Collins AG, Butson PC, Whitwam JG, Young IR. Induction of microcurrents in critically ill patients in magnetic resonance systems. Crit Care Med. 1993; 21:1923-1928.
94. Wacker FK, Hillenbrand CM, Duerk JL, Lewin JS. MR-guided endovascular interventions: device visualization, tracking, navigation, clinical applications, and safety aspects. Magn Reson Imaging Clin N Am. 2005; 13:431-439.
95. Laudon MK, Webster JG, Frayne R, Grist TM. Minimizing interference from magnetic resonance imagers during electrocardiography. IEEE Trans Biomed Eng. 1998; 45:160 -164.
96. Nazarian S, Kolandaivelu A, Zviman MM, Meininger GR, Kato R, Susil RC, Roguin A, Dickfeld TL, Ashikaga H, Calkins H, Berger RD, Bluemke DA, Lardo AC, Halperin HR. Feasibility of real-time magnetic resonance imaging for catheter guidance in electrophysiology studies. Circulation. 2008; 118:223-229.
97. Perazella MA. Gadolinium-contrast toxicity in patients with kidney disease: nephrotoxicity and nephrogenic systemic fibrosis. Curr Drug Saf. 2008; 3:67-75.
98. Sommer T, Naehle CP, Yang A, Zeijlemaker V, Hackenbroch M, Schmiedel A, Meyer C, Strach K, Skowasch D, Vahlhaus C, Litt H, Schild H. Strategy for safe performance of extrathoracic magnetic resonance imaging at 1.5 tesla in the presence of cardiac pacemakers in non-pacemaker-dependent patients: a prospective study with 115 examinations. Circulation. 2006; 114:1285-1292.
99. Nazarian S, Roguin A, Zviman MM, Lardo AC, Dickfeld TL, Calkins H, Weiss RG, Berger RD, Bluemke DA, Halperin HR. Clinical utility and safety of a protocol for noncardiac and cardiac magnetic resonance imaging of patients with permanent pacemakers and implantablecardioverter defibrillators at 1.5 Tesla. Circulation. 2006; 114: 1277-1284.
100. Chen MM, Coakley FV, Kaimal A, Laros RK Jr. Guidelines for computed tomography and magnetic resonance imaging use during pregnancy and lactation. Obstet Gynecol. 2008; 112:333-340.